InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (4 ops.)
Insider track record
ExecutiveDisclosed buys
1
Disclosed sells
4
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the full record of transactions filed by Malik Rajesh, Directeur Médical. Director active across 2 companies, notably G1 Therapeutics, Inc.. Aggregated, 17 reports have been recorded. Breakdown: 1 buy · 4 sells. Total volume traded: €72k. Activity tracked since 10 May 2021. The latest transaction was filed on 5 July 2024 (Cession). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Malik Rajesh
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations17 total
17,900 sharesCommon StockSEC:0000950170-24-107800:0
2,475 shares@ US$2.50776.7% of flowCommon StockSEC:0001562180-24-005658:0
8,151 shares@ US$4.788842.4% of flowCommon StockSEC:0001562180-24-004058:0
28,600 shares@ US$0.309.3% of flowCommon StockSEC:0001562180-24-001296:0
37,300 shares0Common StockSEC:0001562180-24-000326:0
3,700 sharesCommon StockSEC:0001104659-23-129770:0
21,439 shares@ US$0.399.1% of flowCommon StockSEC:0001562180-23-008346:0
1,361 shares@ US$2.45373.6% of flowCommon StockSEC:0001562180-23-005813:0
35,000 shares0Common StockSEC:0001562180-23-004097:0
17,900 shares0Common StockSEC:0001562180-23-000252:0
14,000 shares@ US$0.304.6% of flowCommon StockSEC:0001562180-22-008338:0
3,700 shares@ US$6.66100.0% of flowCommon StockSEC:0001104659-22-122390:0
Canonical exit: 26 Feb 2023 (T+90)
18,000 shares@ US$0.398.3% of flowCommon StockSEC:0001562180-22-006701:0
648 shares@ US$5.17153.8% of flowCommon StockSEC:0001562180-22-005555:0
10,000 shares@ US$0.3026.0% of flowCommon StockSEC:0001562180-22-000955:0
12,000 shares0Common StockSEC:0001562180-22-000305:0
10,000 shares@ US$0.303.1% of flowCommon StockSEC:0001562180-21-003395:0
17 of 17 declarations
About Malik Rajesh
Malik Rajesh is Direct Medical Officer and is involved at G1 Therapeutics, Inc. as Chief Medical Officer and at POINT Biopharma Global Inc. as Director. He has 17 filings in total, and across the 17 sampled filings the buy and sell amounts are 23768 EUR and 48248 EUR, respectively, over the period from 2021-05-11 to 2024-09-18, with Levée d'options as the transaction nature.
